Headlands Technologies LLC Makes New Investment in Establishment Labs Holdings Inc. $ESTA

Headlands Technologies LLC bought a new stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 13,681 shares of the company’s stock, valued at approximately $1,174,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Establishment Labs by 20.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 57,215 shares of the company’s stock worth $2,335,000 after purchasing an additional 9,557 shares during the period. Geode Capital Management LLC lifted its stake in Establishment Labs by 1.2% in the second quarter. Geode Capital Management LLC now owns 25,917 shares of the company’s stock valued at $1,105,000 after purchasing an additional 299 shares during the last quarter. WINTON GROUP Ltd purchased a new position in Establishment Labs in the second quarter valued at approximately $651,000. Nebula Research & Development LLC grew its holdings in Establishment Labs by 27.9% during the second quarter. Nebula Research & Development LLC now owns 16,214 shares of the company’s stock valued at $692,000 after purchasing an additional 3,538 shares during the period. Finally, Sei Investments Co. grew its holdings in Establishment Labs by 13.3% during the second quarter. Sei Investments Co. now owns 48,428 shares of the company’s stock valued at $2,068,000 after purchasing an additional 5,668 shares during the period. 72.91% of the stock is owned by institutional investors.

Analysts Set New Price Targets

ESTA has been the topic of several research reports. Canaccord Genuity Group set a $105.00 target price on Establishment Labs in a research note on Thursday, August 6th. Citigroup raised Establishment Labs from a “neutral” rating to a “buy” rating and set a $92.00 price target on the stock in a research report on Thursday, August 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Establishment Labs in a research note on Wednesday, June 24th. TD Cowen lifted their price objective on Establishment Labs from $95.00 to $117.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. Finally, Needham & Company LLC boosted their price objective on Establishment Labs from $86.00 to $95.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Establishment Labs has a consensus rating of “Moderate Buy” and a consensus target price of $100.25.

Establishment Labs Trading Down 1.9%

Shares of Establishment Labs stock opened at $69.33 on Tuesday. The company’s 50-day moving average price is $84.67 and its 200-day moving average price is $74.92. The company has a current ratio of 3.84, a quick ratio of 2.52 and a debt-to-equity ratio of 12.11. Establishment Labs Holdings Inc. has a 12-month low of $36.53 and a 12-month high of $97.59. The company has a market cap of $2.07 billion, a price-to-earnings ratio of -52.92 and a beta of 1.07.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.05). The firm had revenue of $67.54 million for the quarter, compared to analysts’ expectations of $65.79 million. Establishment Labs had a negative net margin of 15.82% and a negative return on equity of 196.69%. Establishment Labs’s revenue was up 31.7% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.57) EPS. On average, equities analysts expect that Establishment Labs Holdings Inc. will post -1.15 earnings per share for the current fiscal year.

Establishment Labs Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.